vs
Nutex Health, Inc.（NUTX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Nutex Health, Inc.的季度营收约是再鼎医药的1.2倍（$151.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs -41.1%），Nutex Health, Inc.自由现金流更多（$69.0M vs $-26.7M），过去两年Nutex Health, Inc.的营收复合增速更高（50.0% vs 20.8%）
Nutex Health是一家总部位于美国得克萨斯州休斯敦的营利性医疗企业，核心业务为运营各类医疗机构，是美国本土医疗领域的专业运营机构，致力于为当地市场提供相关医疗服务与场地运营支持。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
NUTX vs ZLAB — 直观对比
营收规模更大
NUTX
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出58.2%
-41.1%
自由现金流更多
NUTX
多$95.7M
$-26.7M
两年增速更快
NUTX
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $127.1M |
| 净利润 | $11.8M | — |
| 毛利率 | 30.4% | 51.0% |
| 营业利润率 | 20.4% | -54.6% |
| 净利率 | 7.8% | — |
| 营收同比 | -41.1% | 17.1% |
| 净利润同比 | -80.8% | — |
| 每股收益（稀释后） | $2.34 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUTXZLAB
| Q4 25 | $151.7M | $127.1M | ||
| Q3 25 | $267.8M | $115.4M | ||
| Q2 25 | $244.0M | $109.1M | ||
| Q1 25 | $211.8M | $105.7M | ||
| Q4 24 | $257.6M | $108.5M | ||
| Q3 24 | $78.8M | $101.8M | ||
| Q2 24 | $76.1M | $100.1M | ||
| Q1 24 | $67.5M | $87.1M |
净利润NUTXZLAB
| Q4 25 | $11.8M | — | ||
| Q3 25 | $55.4M | $-36.0M | ||
| Q2 25 | $-17.7M | $-40.7M | ||
| Q1 25 | $21.2M | $-48.4M | ||
| Q4 24 | $61.6M | — | ||
| Q3 24 | $-8.8M | $-41.7M | ||
| Q2 24 | $-364.0K | $-80.3M | ||
| Q1 24 | $-364.0K | $-53.5M |
毛利率NUTXZLAB
| Q4 25 | 30.4% | 51.0% | ||
| Q3 25 | 57.8% | 59.5% | ||
| Q2 25 | 51.2% | 60.6% | ||
| Q1 25 | 55.9% | 63.6% | ||
| Q4 24 | 55.0% | 61.5% | ||
| Q3 24 | 27.8% | 64.1% | ||
| Q2 24 | 29.7% | 64.9% | ||
| Q1 24 | 15.1% | 61.4% |
营业利润率NUTXZLAB
| Q4 25 | 20.4% | -54.6% | ||
| Q3 25 | 48.7% | -42.3% | ||
| Q2 25 | 13.8% | -50.3% | ||
| Q1 25 | 38.1% | -53.3% | ||
| Q4 24 | 44.4% | -62.6% | ||
| Q3 24 | 12.3% | -66.6% | ||
| Q2 24 | 7.0% | -76.0% | ||
| Q1 24 | 2.1% | -80.7% |
净利率NUTXZLAB
| Q4 25 | 7.8% | — | ||
| Q3 25 | 20.7% | -31.2% | ||
| Q2 25 | -7.3% | -37.3% | ||
| Q1 25 | 10.0% | -45.8% | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | -11.2% | -40.9% | ||
| Q2 24 | -0.5% | -80.2% | ||
| Q1 24 | -0.5% | -61.4% |
每股收益（稀释后）NUTXZLAB
| Q4 25 | $2.34 | $-0.05 | ||
| Q3 25 | $7.76 | $-0.03 | ||
| Q2 25 | $-2.95 | $-0.04 | ||
| Q1 25 | $3.33 | $-0.04 | ||
| Q4 24 | $11.56 | $-0.09 | ||
| Q3 24 | $-1.72 | $-0.04 | ||
| Q2 24 | $-0.07 | $-0.08 | ||
| Q1 24 | $-0.08 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $185.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $329.4M | $715.5M |
| 总资产 | $918.5M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NUTXZLAB
| Q4 25 | $185.6M | $689.6M | ||
| Q3 25 | $166.0M | $717.2M | ||
| Q2 25 | $96.7M | $732.2M | ||
| Q1 25 | $84.7M | $757.3M | ||
| Q4 24 | $40.6M | $779.7M | ||
| Q3 24 | $46.9M | $616.1M | ||
| Q2 24 | $40.8M | $630.0M | ||
| Q1 24 | $30.0M | $650.8M |
股东权益NUTXZLAB
| Q4 25 | $329.4M | $715.5M | ||
| Q3 25 | $317.2M | $759.9M | ||
| Q2 25 | $235.3M | $791.7M | ||
| Q1 25 | $176.9M | $810.8M | ||
| Q4 24 | $132.4M | $840.9M | ||
| Q3 24 | $60.4M | $667.7M | ||
| Q2 24 | $62.7M | $704.2M | ||
| Q1 24 | $63.0M | $762.2M |
总资产NUTXZLAB
| Q4 25 | $918.5M | $1.2B | ||
| Q3 25 | $964.5M | $1.2B | ||
| Q2 25 | $841.0M | $1.2B | ||
| Q1 25 | $761.9M | $1.2B | ||
| Q4 24 | $655.3M | $1.2B | ||
| Q3 24 | $438.5M | $985.3M | ||
| Q2 24 | $422.4M | $987.4M | ||
| Q1 24 | $404.3M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $69.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 45.5% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.95× | — |
| 过去12个月自由现金流最近4个季度 | $245.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流NUTXZLAB
| Q4 25 | $70.4M | $-26.0M | ||
| Q3 25 | $99.5M | $-32.0M | ||
| Q2 25 | $27.3M | $-31.0M | ||
| Q1 25 | $51.0M | $-61.7M | ||
| Q4 24 | $54.0K | $-55.8M | ||
| Q3 24 | $6.8M | $-26.8M | ||
| Q2 24 | $13.3M | $-42.2M | ||
| Q1 24 | $3.1M | $-90.1M |
自由现金流NUTXZLAB
| Q4 25 | $69.0M | $-26.7M | ||
| Q3 25 | $99.2M | $-35.0M | ||
| Q2 25 | $26.5M | $-33.9M | ||
| Q1 25 | $50.9M | $-63.2M | ||
| Q4 24 | $-341.0K | $-58.4M | ||
| Q3 24 | $6.2M | $-28.2M | ||
| Q2 24 | $12.7M | $-42.9M | ||
| Q1 24 | $2.3M | $-91.1M |
自由现金流率NUTXZLAB
| Q4 25 | 45.5% | -21.0% | ||
| Q3 25 | 37.0% | -30.4% | ||
| Q2 25 | 10.9% | -31.1% | ||
| Q1 25 | 24.0% | -59.9% | ||
| Q4 24 | -0.1% | -53.8% | ||
| Q3 24 | 7.8% | -27.7% | ||
| Q2 24 | 16.7% | -42.9% | ||
| Q1 24 | 3.4% | -104.5% |
资本支出强度NUTXZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率NUTXZLAB
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
